SAURABH JAUHARI: Open Payments
NPI 1558507707 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$670 in 31 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $26 · 2025 $670
Food & beverage: $670
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $199 |
| Vanda Pharmaceuticals Inc. | 6 | $153 |
| Teva Pharmaceuticals USA, Inc. | 3 | $86 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| E.R. Squibb & Sons, L.L.C. | 2 | $30 |
| Almatica Pharma LLC | 1 | $28 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
Products named: VRAYLAR, FANAPT, AUSTEDO XR, ABILIFY ASIMTUFII, CAPLYTA, COBENFY, LOREEV XR, SPRAVATO.
Industry payments across AZ — which companies pay providers there.
